Image source: Getty Images.
Investors in Keryx Biopharmaceuticals (NASDAQ: KERX), a commercial-stage biopharma focused on renal diseases, had an August their portfolios would like to forget. Shares were obliterated during the month, dropping 44.3%, according to data from S&P Global Market Intelligence.